Non-Fucosylated Anti-Human EphB3 (XPA.04.001) Therapeutic Antibody (CAT#: BioBet-1765ZP) Datasheet

EPHB3

EPH receptor B3

Ephrin receptors and their ligands, the ephrins, mediate numerous developmental processes, particularly in the nervous system. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. The Eph family of receptors are divided into two groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. This gene encodes a receptor for ephrin-B family members.

EPHB3; EPH receptor B3; ETK2; HEK2; TYRO6; ephrin type-B receptor 3; EK2; EPH-like kinase 2; embryonic kinase 2; human embryo kinase 2; EPH-like tyrosine kinase 2; EPH-like tyrosine kinase-2; tyrosine-protein kinase TYRO6

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

XPA.04.001

Murine

Human

This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.

Cancer